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Abstract
Background: The prevalence of transmitted HIV drug resistance (TDR) is stabilizing or decreasing in developed countries.
However, this trend is not specifically evaluated among immigrants from regions without well-implemented antiretroviral
strategies.
Methods: TDR trends during 1996–2010 were analyzed among naı ¨ve HIV-infected patients in Spain, considering their origin
and other factors. TDR mutations were defined according to the World Health Organization list.
Results: Pol sequence was available for 732 HIV-infected patients: 292 native Spanish, 226 sub-Saharan Africans (SSA), 114
Central-South Americans (CSA) and 100 from other regions. Global TDR prevalence was 9.7% (10.6% for Spanish, 8.4% for
SSA and 7.9% for CSA). The highest prevalences were found for protease inhibitors (PI) in Spanish (3.1%), for non-nucleoside
reverse transcriptase inhibitors (NNRTI) in SSA (6.5%) and for nucleoside reverse transcriptase inhibitors (NRTI) in both
Spanish and SSA (6.5%). The global TDR rate decreased from 11.3% in 2004–2006 to 8.4% in 2007–2010. Characteristics
related to a decreasing TDR trend in 2007-10 were Spanish and CSA origin, NRTI- and NNRTI-resistance, HIV-1 subtype B,
male sex and infection through injection drug use. TDR remained stable for PI-resistance, in patients infected through sexual
intercourse and in those carrying non-B variants. However, TDR increased among SSA and females. K103N was the
predominant mutation in all groups and periods.
Conclusion: TDR prevalence tended to decrease among HIV-infected native Spanish and Central-South Americans, but it
increased up to 13% in sub-Saharan immigrants in 2007–2010. These results highlight the importance of a specific TDR
surveillance among immigrants to prevent future therapeutic failures, especially when administering NNRTIs.
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Introduction
The presence of transmitted drug resistance mutations (TDR) in
patients unexposed to highly active antiretroviral treatment
(HAART) is a major problem in the management of HIV-1
infection. Several studies have described a high risk of virological
failure to first therapy in patients harbouring resistance mutations
conferring resistance to any of the drugs received. Nevertheless,
first-treatment guided by initial resistance testing achieves similar
efficacy in patients with primary drug resistance as in patients with
wild-type virus [1–4]. Therefore, international guidelines recom-
mend that initial treatment choice should depend on the HIV
resistant test results prior to starting HAART [5–7].
Numerous works have analysed the TDR prevalence in
Western Europe and the United States. After several years with
a continuous increase in the TDR rate [8–10], the efficacy of
HAART and the development of both new antiretroviral drugs
and classes have led to stable [2,11–14] or decreasing trends
[15,16] of TDR. However, the TDR trends could be intimately
related to the antiretroviral programmes implemented in each
region, but only few studies have reported TDR prevalences according
to the origin of the patients [11,17]. Given that immigrant patients
account for a growing portion of the HIV-infected population in
developed countries, the presence and trends of TDR among this
subgroup should be explored in detail. In Spain, a third of newly
HIV-diagnosed patients are immigrants [18–19], most of them
coming from Central and South America or sub-Saharan Africa.
The special socio-cultural characteristics of these populations as well
as the antiretroviral policies established in their regions of origin
may affect the transmission of resistant variants. Therefore, we
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26757analyze here the changes in the TDR rate through the last 15 years
in a large set of HIV-infected naı ¨ve patients taking into account
their origin.
Materials and Methods
Study population
A total of 732 HIV-1-infected patients diagnosed between 1996
and 2010 with at least one pol sequence prior to any antiretroviral
treatment were included. Most (.98%) were under follow-up in
different HIV/AIDS clinics in Madrid, Spain. The origin of the
patients (i.e., self-reported place of birth) was: 292 native Spanish,
226 sub-Saharan Africans (SSA), 114 Central and South
Americans (CSA), 26 East Europeans (including Russia), 20 West
Europeans and North Americans, 3 North Africans, 2 Asians and
49 of unknown origin. The most frequent countries of origin for
SSA were Equatorial Guinea (111 patients), Nigeria (28), Sierra
Leone (10) and Liberia (7). For CSA, Ecuador (20), Argentina (15),
Colombia (14), Brazil (13) and Cuba (13). For East Europeans
Romania (10) and Russia (7). Finally, for West Europeans, the
most frequent origins were France and Portugal (6 each). Both
protease (PR) and reverse transcriptase (RT) sequences were
available for 641 patients, only PR sequence for 89 patients and
only RT for 2 patients. Most (495, 67.6% [CI: 64.2271]) of the
HIV-1 sequences included had been previously published [20–21].
The remaining were collected from Hospital Ramo ´n y Cajal
(n=218) and Hospital Doce de Octubre (n=19) in Madrid, Spain.
This study was part of a project approved by the review board of
the Hospital Ramo ´n y Cajal Clinical Research Ethical Committee.
It was designed to protect the rights of all subjects involved under
the appropriate local regulations. To maintain subject confiden-
tiality, a unique ID number was assigned to each specimen, and
written consent obtained for each patient by clinicians.
Drug resistance
The prevalence of transmitted drug resistance was defined
according to the list of mutations for TDR surveillance as
recommended by the World Health Organization [22] using the
Calibrated Population Resistance tool [23]. Genotypic interpre-
tation of these resistance mutations was evaluated using the
Stanford HIVdb Algorithm [24], version 6.0.11. Resistance was
normalized in three levels: susceptible (S), intermediate (I), and
resistant (R).
HIV-1 subtyping
HIV-1 subtypes and circulating recombinant forms (CRF) were
identified by phylogenetic analysis of the pol sequences. The 2008
version of the subtype reference dataset provided by Los Alamos
National Laboratory was used. At least two representative se-
quences of each 9 subtypes and the 43 CRF of HIV-1 group M
available at the moment of the analysis were taken as references.
DNA sequences were aligned using the ClustalX 2.0.11 program.
The tree topology was obtained using the Neighbour-Joining
method. The pairwise distance matrix was estimated using the
Kimura two-parameter model within the DNAdist program, as
implemented in the PHYLIP software package. Bootstrap re-
sampling (1,000 data sets)ofthemultiplealignmentswasperformed,
with the bootstrap cut-off set at 700.
Statistical analysis
Prevalences were expressed in percentage and 95% confidence
interval (CI). Continuous variables were compared using the
t-test. Categorical variables were compared using the chi-square
test or Fisher’s exact test if appropriate. Association between
epidemiological, clinical and virological factors was analysed by
univariate and multivariate logistic regression. The maximum
model included the variables of origin of the patient, route of HIV
infection, HIV subtype and time period of infection. Changes over
time in the resistance prevalences were analysed using a chi-square
test for trends (linear-by-linear association). Significance was set at
p,0.05.
Results
TDR prevalence (i.e., to any antiretroviral drug class) among
the 732 patients diagnosed in Madrid, Spain, between 1996 and
2010 was 9.7% (CI: 7.6211.8) (Figure 1). Table 1 shows the
main characteristics of the population comparing patients infected
with wild-type viruses with those harbouring TDR. Regarding the
antiretroviral drug class, TDR prevalence among patients in our
study was 2.9% (CI: 1.724.1) for PR inhibitors (PI) (3.1% [CI:
1.125.1] in Spanish, 1.8% [CI: 0.123.5] in SSA and 1.7% [CI:
20.724.2] in CSA), 6.1% (CI: 4.227.9) for nucleoside reverse-
transcriptase inhibitors (NRTI) (6.4% [CI: 3.629.3] in Spanish,
6.5% [CI: 2.8–10.2] in SSA and 5% [CI: 0.729.4] in CSA), and
5.4% (CI: 3.727.2) for non-nucleoside RT inhibitors (NNRTI)
(5% [CI: 2.527.6] in Spanish, 6.5% [CI: 2.8–10.2] in SSA and
4% [CI: 0.2–7.9] in CSA). To assess the TDR prevalence
according to the calendar year, sequences were grouped in three
periods (2000-03, 2004-06 and 2007-10) according to the observed
resistance trend by calendar year. Sequences obtained before year
2000 were included in the global estimates but excluded in the
analyses due to their low number (n=32) and representativeness
since all were sequences from immigrant patients. In the whole
study population, the TDR prevalence to any antiretroviral drug
was 10.6% (CI: 5.3215.9), 11.3% (CI: 7.8214.8) and 8.4% (CI:
5211.8) in those periods, respectively (p trend=0.35). In the
following paragraphs, the TDR prevalences and temporal trends
in these periods are detailed according to different factors.
According to drug class
As observed in the global TDR prevalence, the presence of
transmitted PI-resistance mutations reached a maximum in 2004-
06 (4.1% [CI: 1.926.3]), and declined to its minimum value (1.6%
[CI: 023.2]) in the last period (2007-10) (p trend=0.23). On the
other hand, rates of both NRTI- and NNRTI-resistance declined
progressively and significantly along the three periods: 13.2% (CI:
5.2221.3), 6.1% (CI: 3.428.7) and 4.4% (CI: 1.926.9), for NRTI
(p trend=0.03) and 10.3% (CI: 3.1217.5), 5.8% (CI: 3.228.4)
and 3.6% (CI: 1.325.9), for NNRTI (p trend=0.04). This decline
was more pronounced for NRTI-resistance mutations, getting
closer to the NNRTI-resistance mutations rate in the last period
(Figure 2a). Thus, transmitted resistance to RT inhibitors was
two or threefold higher than that for PI in 2007-10 (p=0.06).
According to HIV-1 variant
Subtype B was found in 383 (52.3%, [CI: 48.7–55.9]) patients,
meanwhile non-B subtypes and recombinants infected 349 (47.7%
[CI: 44.1–51.3]) patients. Among them, the most frequent variants
were: CRF02_AG (128 patients), subtype A (36), subtype G (35),
CRF12_BF (23) and subtype C (22). Although global TDR
prevalence was similar in subtype B and in non-B variants (10.2%
[CI: 7.1–13.2] vs. 9.2% [CI: 6.1–12.2], p=0.64) their TDR
temporal trend was different (Figure 2b): in subtype B, TDR
declined from 12.5% (CI: 3.1221.9) in 2000-03 to 6.8% (CI: 2.3–
11.4) in 2007-10 (p trend=0.16), but in non-B variants this
prevalence remained stable (9.5% [CI: 3.2–15.8] and 9.8% [CI:
4.7–14.8], respectively [p trend=0.99]). Of note, TDR was higher
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2.3–11.4], p=0.54) in the last period.
According to the origin of patients
Global TDR prevalences were 10.6% (CI: 7.1–14.1) in native
Spanish, 8.4% (CI: 4.8–12) in SSA and 7.9% (CI: 2.9–12.8) in
CSA (Figure 1). Regarding the temporal trends in each
population (Figure 2c), TDR declined constantly in Spanish
natives: 13.2% (CI: 2.41–23.9) in 2000-03, 11.8% (6.7–17) in
2004-06 and 8% (CI: 2.7–13.3) in 2007-10 (p trend=0.28). In
CSA, no TDR mutations were detected in 2000-03, but TDR
reached similar rates as in natives in the following periods: 10.2%
Figure 1. Prevalence of TDR to each drug class according to the origin of the patients. TDR, transmitted drug resistance; NRTI, nucleoside
reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; n, number of patients.
doi:10.1371/journal.pone.0026757.g001
Table 1. Comparison of characteristics between patients infected with virus harbouring TDR and patients infected with wild-type
virus.
Total With TDR Wild-type p value OR (95% CI) in univariate analysis
Patients (n) 732 71 (9.7) 661 (90.3) -
Origin [n (%)]
Spain 292 (39.9) 31 (43.7) 261 (39.5) 0.5 1
SSA 226 (30.9) 19 (26.8) 207 (31.3) 0.4 0.77 (0.42–1.40)
CSA 114 (15.6) 9 (12.7) 105 (15.9) 0.47 0.73 (0.33–1.58)
Other 100 (13.7) 12 (16.9) 88 (13.3) 0.38 1.15 (0.57–2.33)
Sex [n (%)]
a
Male 469 (68.6) 47 (69.1) 422 (68.5) 0.92 1
Female 215 (31.4) 21 (30.9) 194 (31.5) 0.92 1.67 (0.50–5.58)
Route of transmission [n (%)]
b
Heterosexual contact 269 (49.4) 23 (44.2) 246 (50.0) 0.43 1
Homo/bisexual contact 196 (36.0) 18 (34.6) 178 (36.2) 0.82 0.90 (0.46–1.78)
Injection drug use 68 (12.5) 9 (17.3) 59 (12.0) 0.27 1.58 (0.73–3.41)
Other 11 (2.0) 2 (3.8) 9 (1.8) 0.33 1.22 (0.70–2.12)
HIV-1 Subtype [n (%)]
B 383 (52.3) 39 (54.9) 344 (52.0) 0.64 1
Non-B 349 (47.7) 32 (45.1) 317 (48.0) 0.64 0.89 (0.54–1.46)
Year of HIV-1 Infection [n (%)]
,2000 32 (4.4) 0 (0) 32 (4.8) - 0
2000-03 132 (18.0) 14 (19.7) 118 (17.8) 0.82 1
2004-06 318 (43.4) 36 (50.7) 282 (42.7) 0.19 1.08 (0.56–2.07)
2007-10 250 (34.1) 21 (29.6) 229 (34.6) 0.39 0.78 (0.38–1.58)
TDR, transmitted drug resistance; OR, odds ratio; CI, confidence interval; n, number of patients; SSA, sub-Saharan Africa; CSA, Central and South America.
aData available for 684 patients.
bData available for 544 patients.
cData available for 541 patients.
doi:10.1371/journal.pone.0026757.t001
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patients (as self-reported birth place); D) sex of the patients; and E) risk practice. TDR, transmitted drug resistance; NRTI, nucleoside reverse
transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; SSA, sub-Saharan Africa; CSA, Central and
South America; Htsex, heterosexual contact; Homo, homo/bisexual contact; IDU, injection drug use. The p-values shown next to the lines and sharing
color code correspond to the chi-square test for trend in each case.
doi:10.1371/journal.pone.0026757.g002
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trend=0.47). In contrast, among SSA the TDR prevalence
remained stable in 2000-03 and 2004-06 (7.7% [CI: 1.2–14.2] in
both cases) and rose up to 13% (CI: 5.1–21) in 2007-10 (p
trend=0.27). Thus SSA presented the highest TDR frequency in
the last period. Finally, TDR prevalence was very high among
East Europeans (5/26, 19.2% [CI: 4.1–34.4]) and West Europeans
(3/20, 15% [CI: 20.6–30.6]), although the low number of patients
did not allow to differentiate the prevalence according to temporal
trend.
According to sex of the patients
Most (68.6% [CI: 65.1–72]) of the subjects with available data
were males (Table 1). Global TDR prevalence was similar
between them and females (10% [CI: 7.3–12.7] vs. 9.8% [CI: 5.8–
13.7], respectively, p=0.97). Although this similarity was observed
in 2000-03 (9.7% [CI: 2.3–17] vs. 11.3% [CI: 3.4–19.2]), TDR
increased among male patients but decreased among females in
2004-06 (13% [CI: 8.7–17.4] vs. 8.5% [CI: 1.4–15.6], p=0.46)
and vice versa in 2007-10 (6.6% [CI: 2.8–10.3] vs. 12.5% [CI: 4.9–
20.1], p=0.21).
According to route of HIV infection of the patients
Half (49.4% [CI: 45.2–53.6]) of the patients with known route
of transmission had been infected through heterosexual inter-
course (Table 1). TDR prevalence was higher (13.2% [CI: 5.2–
21.3]) in injection drug users (IDU) and similar in those infected
through homo/bisexual (9.2% [CI: 5.1–13.2]) and heterosexual
(8.5% [CI: 5.2–11.9]) intercourse. Regarding the temporal trend,
there was a drastic decrease in the TDR rate among IDU (n=68),
the most common risk practice in Spain until the late 90 s. This
rate was 23.5% (CI: 3.4–43.7; 4/17 patients) in 2000-03, 14.8%
(CI: 1.4–28.2; 4/27) in 2004-06 and 4.3% (CI: 24–12.7; 1/23) in
2007-10 (p trend=0.08). Among homo/bisexuals, the prevalence
rose from 2000-03 (4.7% [CI: 24.3–13.9]) to 2004-06 (12.6% [CI:
6.44–18.8]) but decreased to the initial level in the last period
(4.7% [CI: 20.5–10]) (p trend=0.36). Finally, the TDR rate in
heterosexuals seemed to stabilize after an increase from 2000-03
(4.4% [CI: 20.5–9.3]) to 2004-06 (12.3% [CI: 4.8–19.9]), and was
the risk practice with the highest TDR prevalence in 2007-10
(10% [CI: 4.1–15.9]) (p trend=0.32).
Patients infected with viruses harbouring TDR mutations
Among the 71 patients harbouring TDR mutations (Table 1),
31 were Spanish, 19 SSA, 9 CSA, 5 East Europeans, 3 West
Europeans, 1 North African and 3 of unknown origin. In three
quarters (53, 74.6% [CI: 64.2–84.8]) of the cases, TDR affected
only a single drug class. However, in 6 patients (4 Spanish, 1 SSA
and 1 CSA) a triple-class resistance was found. The pattern of
TDR mutations was different for NRTI- and PI-resistance
according to the origin (Figure 3). Among SSA, RT-M184I/V
and PR-M46L were the most frequent mutations, respectively,
meanwhile in both Spanish natives and CSA, RT-T215rev and
PR-V82A were the most prevalent substitutions. For NNRTI-
resistance, K103N was the most frequent mutation in all groups,
although its prevalence was higher in SSA (4.7% [CI: 1.5–7.8]). In
fact, K103N was the most prevalent mutation in all periods, and it
was the mutation found in a third of the cases (15/45) where a
single TDR mutation was found. The temporal trend of specific
mutation prevalences showed significant reductions from 2000-03
to 2007-10 for tymidine-analogue mutations together (8.8% [CI:
2.1–15.6] to 2.4% [CI: 0.5–4.3], p trend=0.03) and K103N
(10.3% [CI: 3.1–17.5] to 3.2% [CI: 1–5.4], p trend=0.02) and
non-significant reduction for M184I/V (4.4% [CI: 20.5–9.3] to
2.4% [CI: 0.5–4.3], p trend=0.67). In the logistic model
(Table 1), there was no significant difference in the prevalence
of TDR according to sex, year or route of HIV-1 infection or
origin of the patients.
Figure 3. Prevalence of individual mutations among the patients infected with HIV-1 variants harbouring any TDR. SSA, sub-Saharan
Africa; CSA, Central and South America; PI, protease inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse
transcriptase inhibitors.
doi:10.1371/journal.pone.0026757.g003
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The analysis of the genotypic resistance interpretation of the 71
pol sequences harbouring TDR (Figure 4) revealed that especially
in the case of PI there are options to select a fully active drug even
in patients carrying PI-resistance mutations if the treatment choice
is guided by the resistance test. Actually, none of the 21 patients
with PI-resistance mutations presented high resistance levels to all
PI tested due to their susceptibility to new-generation drugs like
darunavir or tipranavir. Among the 39 patients with NRTI-
resistance mutations, only 5 (12.8% [CI: 2.3–23.3]) presented
some level of resistance to all NRTI included. Furthermore, 14
(35.9% [CI: 20.8–50.9]) and 16 (41% [CI: 25.6–56.5]) were fully
susceptible to the most used NRTI combinations, emtricitabine/
tenofovir and lamivudine/abacavir. Regarding NNRTI-resis-
tance, none of the 34 patients with resistance mutations was fully
susceptible to efavirenz and nevirapine, the most used drugs of this
class. Only etravirine would have some level of activity in these
patients.
Differences in HIV viral load
Patients infected with HIV variants harbouring TDR presented
a significantly lower mean viral load compared to those infected
with wild-type HIV (4.1 log [SD: 0.83] vs. 4.4 log [SD: 0.83] RNA-
HIV-1 copies/ml, p=0.03). This result was also obtained when
comparing patients infected with viruses carrying or not the
mutation M184I/V (3.9 log [SD: 0.86] vs. 4.4 log [SD: 0.83],
p=0.04). In addition, according to sex, male patients presented a
significantly higher viral load than female patients (4.5 log [SD:
0.79] vs. 4.2 log [SD: 0.89], p,0.001) at diagnosis time. There
were no differences in plasma HIV viraemia according to origin,
risk practice, HIV infection year or HIV subtype in the study
population.
Transmission clusters
Phylogenetic analyses only revealed a cluster of drug-resistance
mutations transmission. This involved a native Spanish and a
Chilean diagnosed in 2006 in the same clinic and infected with
three-drug class resistant subtype B viruses. Both specimens
harboured mutations F53L and L90M at PR and M41L, K103N,
L210W and T215D at RT.
Discussion
This study explores the evolution of TDR rates through 15
years (1996–2010) in a large set of HIV-infected naı ¨ve patients
diagnosed in Spain taking into account different factors: drug class,
viral variant, origin of the patient, route of infection and sex. The
global TDR prevalence reported in this work (9.7%) is in
agreement with the most representative European studies, where
this rate has stabilized around 10% [1,11,12,15]. In the USA, the
TDR prevalence has traditionally been higher, but it also has
started to stabilize [4,25]. According to our results, the rate of
transmitted NRTI-resistance is clearly dropping in Spain until
reaching the levels of NNRTI-resistance, as already reported in
other developed countries [11,15]. In addition, in three quarters of
the cases the transmission of resistance is limited to a single class.
The stabilization of TDR rates is partially due to the high
efficacy of the HAART in Europe, where there is universal access
to this treatment. However, in other regions where treatment is
not available to all HIV-infected people on a regular basis,
emergence and transmission of HIV resistant variants is likely to
happen. Thus, it could be assumed that the TDR trend previously
reported in developed countries will be observed in developing
regions as treatment programmes are implemented. According to
this, low TDR prevalences found in the last years in regions with
shorter HAART tradition [26–27] are expected to be followed by
a peak as seen in Europe around years 2002-03. This has been
reported in African regions with an older treatment scale-up [28–
30]. Here, we describe a growing TDR prevalence among sub-
Saharan patients (SSA) in contrast to the native HIV-infected
population and the general trends reported in West Europe. A
high rate of losses to follow-up has been described among SSA
under treatment in Spain probably due to a low educational level
and their high geographic mobility looking for work [31]. Due to
an ineffective follow-up, drug-resistance variants can be emerging
and circulating among treated SSA and eventually producing
TDR events within this subgroup. Given that SSA patients
Figure 4. Predicted susceptibility to antiretroviral drugs of the 71 viruses carrying TDR mutations. Susceptibility was estimated
according to the HIVdb Interpretation Algorithm (Stanford University, Palo Alto, CA, USA). TDR, transmitted drug resistance; PI, protease inhibitors:
nelfinavir (NFV); atazanavir/r (ATV/r), indinavir/r (IDV/r), fosamprenavir/r (FPV/r), saquinavir/r (SQV/r), lopinavir/r (LPV/r), tipranavir/r (TPV/r) and
darunavir/r (DRV/r), where ‘‘/r’’ indicates co-administration with low-dose ritonavir (RTV) for pharmacological ‘‘boosting’’. NRTI, nucleoside reverse
transcriptase inhibitors: lamivudine (3TC), emtricitabine (FTC), abacavir (ABC), didanosine (ddI), zidovudine (AZT), stavudine (d4T), tenofovir (TDF).
NNRTI, non-nucleoside reverse transcriptase inhibitors: nevirapine (NVP), delavirdine (DLV), efavirenz (EFV), etravirine (ETR); R, high level resistance; I,
intermediate resistant; S, susceptible.
doi:10.1371/journal.pone.0026757.g004
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return afterwards to Africa, transmission of HIV resistant variants
within this collective could be happening either in Africa or in
Spain. Thus, the observed increasing TDR trend among infected
SSA in our study population, the high prevalence of HIV-1 non-B
variants in that collective, and the different NRTI-resistance TDR
pattern found in SSA than in native Spanish, would strongly
suggest that SSA in Spain could have acquired the infection in
their countries of origin or in Spain through infected Africans
carrying resistant viruses.
On the other hand, we observed an absence of TDR in 2000-03
among the 18 CSA in our cohort. However, TDR rates reached
similar levels as in native Spanish in the following periods. This
could be due to the low number of CSA patients included in the
first period or to the limited scale up access to treatment in these
regions. Nowadays, TDR trends in CSA patients are expected to
be similar to trends among Spanish because antiretroviral therapy
programmes have been working in most of these countries for at
least a decade [32]. Also the presence of non-B variants typical
from certain regions of Central and South America (CRF12_BF in
Argentina and Chile and CRF23_BG in Cuba) among CSA
patients harbouring resistant strains suggests that these infections
probably occurred before arriving to Spain. Despite their low
representation, both East and West Europeans (26 and 20 patients,
respectively) showed TDR prevalences beyond 15%. Nevertheless,
these patients infected with resistance variants were diagnosed
before 2006, and were IDU in most cases, both characteristics
related to a higher TDR prevalence according to our results.
Focusing on the HIV subtype, we describe a higher TDR
prevalence in the last study period (2007-10) in patients carrying
non-B variants versus subtype B. This was due to the TDR decrease
among subtype B in contrast to its stabilization among non-B
variants. This is in agreement with other studies reporting growing
TDR rates in non-B versus subtype B [20,33]. However, most
studies [11–13,15] report higher TDR rates in subtype B, although
all of them describe the absolute prevalences in the entire study
period and not the temporal trends according to the subtype. Our
results could be misleading due to the high prevalence of non-B
subtypes and recombinants among SSA patients. Actually,
excluding SSA patients, non-B variants showed a decreasing
TDR prevalence from 15.8% to 6.1% in the first and last period,
respectively (results not shown). Therefore the increase was
probably due to the origin, not to the subtype. On the other
hand, the correlation between HIV subtype and birth place of the
patients could also have confused the different mutational pattern
described: the preferential presence of NRTI-resistance mutation
M184I/V in SSA compared to T215revertants in Spanish and
CSA could appear to be associated to the infection by non-B
variants and subtype B, respectively, as reported in other countries
[34,35]. However, the different antiretroviral strategies imple-
mented in these regions could also be a probable cause of this
different mutational pattern in the studied naive HIV-1-infected
patients carrying resistant viruses.
Our observation of a lower viral load among patients infected
with variants carrying M184I/V has previously been described
[36] due to the fitness reduction related to its acquisition. In
addition, the lower viral load in female versus male at baseline has
already been observed [37]. Regarding the analysis according to
the route of infection, the decrease of the TDR rate among IDU
across the years is a consequence of the evolution of HIV
epidemics in Spain and a better treatment compliance among the
IDU population. In the late 90 s the use of injecting drugs was by
far the first route of HIV infection, but clearly decreased while
HIV transmission due to unprotected sexual contacts increased [19].
According to the genotypic resistance interpretation, the TDR
mutations found in 71 patients mainly affect the NNRTI-based
therapy, the first choice in Spain for naı ¨ve patients [7], due to the
presence of K103N, the most frequent mutation in the study
especially among SSA. Despite its transmission as a singleton
mutation, K103N seriously compromises the use of efavirenz or
nevirapine. Only etravirine, the second-generation NNRTI
approved solely for salvage regimens, could have some level of
activity in these patients. Therefore, resistance testing prior to first-
line treatment choice is strongly recommended. In developed
countries there are therapeutic options as new generation NNRTI,
PI or even new classes as integrase or entry inhibitors. Unfor-
tunately, all these options are not available in developing regions
where NNRTI-resistance among naı ¨ve patients is rising [28].
Interestingly, the highest NNRTI-resistance prevalence in our
study was found among SSA, although in some cases this could
possibly be explained by unrecorded, prophylactic use of
nevirapine in Africa. Our results also suggest that PI could be
active in most naı ¨ve patients carrying PI-resistance mutations if the
treatment choice were guided by the resistance test.
The main limitation of this study is the restricted number of
patients which prevents a solid statistical support of the TDR
trends, for instance analyzing East and West Europeans living in
Spain. The delimitation of the study periods could also be a source
of bias despite the fact they were selected to reflect the trend by
calendar year as accurately as possible. In addition, sub-Saharan
patients might be overrepresented due to the special care they
receive in the Tropical Medicine Units ascribed to the clinics
included in the work, especially patients from Equatorial Guinea, a
former Spanish colony located between Cameroon and Gabon.
Nevertheless, since the year 2000 the immigration in Spain has
increased exponentially, particularly in Madrid, where 17% of the
general population were foreigners in 2010. Finally, the surpris-
ingly high rate in native Spanish of RT-M184I/V (4.4%), a
mutation rapidly cleared due to its cost in terms of viral fitness
[38], might reflect an unrecorded previous treatment exposure in
some patients.
In summary, TDR prevalence in Spain follows the general
trend in Western Europe. The TDR rate is decreasing especially
for NRTI-resistance. However, the TDR trends during 2000–
2010 differed according to the origin of the patients. Whereas in
native Spanish and Central-South Americans the TDR rate is
decreasing, we report for the first time an increasing TDR
prevalence among sub-Saharan patients diagnosed in Spain, who
form the collective with the highest TDR prevalence in Spain
since 2007. This could be due to the special socio-cultural
characteristics of these patients, which may compromise antiret-
roviral treatment compliance and follow-up. Since TDR is
expected to increase in developing regions as treatment is
implemented, the presented results highlight the importance of a
specific TDR surveillance among immigrants living in high-
income countries to prevent future therapeutic failures, especially
when administering NNRTI due to the high K103N prevalence.
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